Drug-Eluting Stent Study Evaluating a New Technology in Patients with Symptomatic Ischemic Heart Disease due to Coronary Artery Blockage.

Trial Profile

Drug-Eluting Stent Study Evaluating a New Technology in Patients with Symptomatic Ischemic Heart Disease due to Coronary Artery Blockage.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Ischaemic heart disorders
  • Focus Therapeutic Use
  • Acronyms DESOAW-FIM; DIRECT; DIRECT-I
  • Sponsors Svelte Medical Systems
  • Most Recent Events

    • 23 May 2013 Final 6 and 12-month results were presented at the 2013 EuroPCR meeting and have been published in EuroIntervention, according a Svelte Medical Systems media release.
    • 30 Jan 2013 Positive 6-month results have been reported in a Svelte Medical Systems media release. Final 6-month data will be presented at a medical symposia later in 2013.
    • 30 Jan 2013 All trial endpoints, including the primary endpoints 'Target-vessel-failure-rate' and 'Late-loss', have been met according to a Svelte Medical Systems media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top